Genzyme Hits Medicis With IP Suit Over Wrinkle Fillers

Law360, New York (October 18, 2010, 2:25 PM EDT) -- Genzyme Corp. has slapped Medicis Pharmaceutical Corp. with a suit alleging that the specialty pharmaceutical company's facial wrinkle treatments infringe one of the plaintiff's patents.

Genzyme filed its complaint Friday in the U.S. District Court for the District of Massachusetts, claiming that Medicis' injectable wrinkle fillers Restylane, Perlane, Restylane-L and Perlane-L infringe U.S. Patent Number 5,399,351, titled “Biocompatible viscoelastic gel slurries, their preparation and use.”

The complaint was filed on behalf of the plaintiff by Alison E.H. McLaughlin, Christopher J. Harnett, James F. Haley Jr. and...
To view the full article, register now.